Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Company Overview & Stock Snapshot Pfizer Inc. is one of the world’s largest pharmaceutical companies, known for household-name drugs and vaccines. Headquartered in New York, Pfizer manufactures treatments across vaccines, oncology, immunology, cardiology, and more. The company gained global prominence for its COVID-19 vaccine (Comirnaty) and antiviral pill (Paxlovid). However, with the pandemic’s tide receding, Pfizer’s stock (PFE) has faced significant challenges in 2023–2025. Shares that once traded above $50 during the vaccine rollout now hover in the mid-$20sreuters.com. At around $24–$25 per share, Pfizer’s market cap is about $138 billionstockanalysis.com – substantially smaller than several years ago and dwarfed
Cipher Mining Stock Skyrockets on Blockbuster AWS Deal – Latest Earnings, Expert Insights & Price Forecast

Cipher Mining Stock Skyrockets on Blockbuster AWS Deal – Latest Earnings, Expert Insights & Price Forecast

Stock Performance and Recent Trends (Past Week) Cipher Mining’s stock has been on a tear. In the final week of October into early November 2025, CIFR rocketed from the high teens to the mid-$20s per sharestockanalysis.comstockanalysis.com. On Monday, Nov 3, shares opened slightly down but closed up over 22% in a single session247wallst.com – an eye-popping move for a mid-cap stock. This surge was directly catalyzed by the company’s Q3 earnings release and strategic partnership news (more on that below). By mid-day Nov 5, CIFR was trading around $25 (+11% intraday)stockanalysis.com, marking roughly a 35% gain week-to-date and a new
Rubico (RUBI) Stock in Freefall: Top Ships Spin-Off Collapses 90% – What Investors Should Know

Rubico (RUBI) Stock in Freefall: Top Ships Spin-Off Collapses 90% – What Investors Should Know

Company Overview: Business Model & Background Rubico Inc. is a Marshall Islands-incorporated shipping company providing crude oil transportation services via a small fleet of tankersglobenewswire.comglobenewswire.com. The company was created as a spin-off from TOP Ships Inc., a Greek tanker owner, to separately house two Suezmax oil tankers (M/T Eco Malibu and M/T Eco West Coast)stocktwits.com. Both 2021-built vessels are “eco” fuel-efficient tankers on long-term time charter contracts with Clearlake (a major commodity trading firm), ensuring stable charter revenue streamsrivieramm.com. Rubico’s strategy focuses on owning and operating these modern tankers, leveraging their high specification and scrubber-fitted fuel efficiency to attract charterersglobenewswire.com.
First Majestic Silver (AG) Shines on Silver’s Surge – But Can the Rally Sustain?

First Majestic Silver (AG) Shines on Silver’s Surge – But Can the Rally Sustain?

Stock Performance and Technical Trends First Majestic’s stock has had a rollercoaster year, skyrocketing through 2025 alongside the price of silver. The share price climbed from the ~$5 level in January to a 52-week high of $15.69 by late Octoberreuters.com, vastly outperforming broader mining indices. This 158% year-to-date surge was propelled by optimism around the Los Gatos acquisition and leverage to silver’s historic rallyinvesting.com. Recent weeks have seen some consolidation. After the Q3 earnings miss in early November, AG pulled back roughly 20–30% from its peak, dipping into the low $10sreuters.com. Technical indicators reflect this cooling momentum: the stock broke
Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Stock Price & Recent Performance 📈 Rigel’s stock has been on a tear in 2025, reflecting its improving fundamentals. As of November 5, 2025, RIGL trades around $38/share, up over 30% in a single day after its blowout Q3 earnings reportstockanalysis.com. The post-earnings volatility has been extreme – initially, shares fell ~7–8% in after-hours trading on Nov. 4 despite the strong results, possibly due to profit-taking or tempered forward outlook, dipping to about $30.32investing.com. However, sentiment swiftly reversed: by the next trading session, buyers piled in, and Rigel stock skyrocketed to new multi-month highs. The stock is now only a
Lumentum Stock Skyrockets on AI Boom – Record Sales & Bold Forecast

Lumentum Stock Skyrockets on AI Boom – Record Sales & Bold Forecast

Recent News: Earnings Spark Rally Lumentum’s San Jose headquarters. The company’s stock jumped after it announced record quarterly revenue and upbeat guidance, fueled by surging demand from AI data centers. Lumentum made headlines on November 4–5, 2025 with a stellar earnings report that ignited its stock. The firm announced Q1 FY2026 (quarter ended Sep 27, 2025) results featuring record-high sales of $533.8 million – about 58% higher than a year agosimplywall.st and even slightly above Wall Street’s consensus (FactSet had ~$526M)marketscreener.com. This top-line feat, the largest quarterly revenue in Lumentum’s 10-year historyoptics.org, was driven by unprecedented demand from AI and
Kratos Defense (KTOS) Soars 300% on Drone Boom – Is the Rally Sustainable?

Kratos Defense (KTOS) Soars 300% on Drone Boom – Is the Rally Sustainable?

1. Company Background and Overview of Kratos Defense & Security Solutions, Inc. Kratos Defense & Security Solutions, Inc. is a U.S. technology company serving the defense and national security market. Founded in 1994 and headquartered in San Diego, Kratos specializes in mission-critical systems for military and government agenciesinvesting.com. The company operates through two main segments – Kratos Government Solutions (KGS) and Unmanned Systems (US) – offering a wide array of products and services. These include satellite ground communication systems, jet-powered unmanned aerial vehicles (UAVs), missile and radar system solutions, advanced propulsion systems for missiles/spacecraft, cyber security and training platforms, and
Babcock & Wilcox (BW) Stock Skyrockets on AI Power Deal – Key Facts, Q3 Earnings & 2025 Outlook

Babcock & Wilcox (BW) Stock Skyrockets on AI Power Deal – Key Facts, Q3 Earnings & 2025 Outlook

(Each of these points is explored in detail below.) Company Overview Babcock & Wilcox Enterprises, Inc. (“B&W”) is an American energy technology and services provider with a 158-year legacy. Headquartered in Akron, Ohio, the company is historically renowned for its steam boilers used in power generation Wikipedia. Today, B&W’s offerings span advanced energy and environmental solutions for industrial and utility markets worldwide Tipranks. It engineers and supplies equipment for power generation (including waste-to-energy and fossil fuel plants), emissions control systems (like scrubbers and carbon capture), and related services/parts. B&W operates through three segments: Renewable, Environmental, and Thermal. The B&W Thermal
Trex Stock Plunges on Earnings Miss – What’s Next for the Decking Leader?

Trex Stock Plunges on Earnings Miss – What’s Next for the Decking Leader?

Market Performance and Recent Stock Price Trex stock has endured a steep slide in 2025, culminating in a dramatic plunge after its early November earnings announcement. On November 5, 2025, TREX opened around $34–35 per share – down roughly 26% from the prior day’s close Streetinsider. This selloff pushed the stock to fresh 52-week lows, shattering the previous low of ~$46 Finviz. Prior to the earnings drop, Trex had already been trending downward for months; with this latest collapse, shares have lost about 50% of their value year-to-date Finviz and over 50% from 12-month highs (which were near $80 Finviz).
From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

Company Overview: AI-Powered Biotech at the Intersection of Therapeutics & Biodefense Lunai Bioworks Inc. is a pre-clinical stage biotechnology company pioneering an unusual dual focus: AI-driven drug discovery and biodefense. The company’s mission is to “capture biological signals at scale, decode them with AI, and rapidly validate insights in model systems”, bridging cutting-edge computation with experimental biotechainvest.comainvest.com. In practical terms, Lunai is developing both therapeutic platforms (for diseases like cancer and neurodegeneration) and advanced diagnostics/screening tools (including detecting chemical/biological threats), all underpinned by machine learning. Core Technology & Pipeline: Lunai’s flagship approach is a next-generation allogeneic dendritic cell (DC) therapy
Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

FDA Setback: Complete Response Letter Halts Lead Drug Ambitions Biohaven’s recent troubles center on VYGLXIA (troriluzole) – its lead drug candidate for spinocerebellar ataxia (SCA), a degenerative brain disorder that currently has no approved treatmentreuters.com. On November 4, 2025, after market close, Biohaven announced that the FDA had issued a Complete Response Letter (CRL) rejecting the company’s New Drug Application. This CRL cited multiple concerns with Biohaven’s data: potential bias, design limitations, lack of pre-specification, and unmeasured confounding factors in the supporting studiesstocktwits.comstocktwits.com. In simpler terms, the FDA was uneasy with how Biohaven ran and analyzed its trials – particularly
Why Zeta Global (ZETA) Stock Is Soaring: 17 Straight Beats, AI Power, and Big Upside Ahead

Why Zeta Global (ZETA) Stock Is Soaring: 17 Straight Beats, AI Power, and Big Upside Ahead

Latest News & Catalysts (Early November 2025) Zeta Global made headlines on November 4, 2025 by reporting stellar third-quarter results and raising its guidance for the 17th straight quarterinvestors.zetaglobal.com. The Q3 earnings release showed better-than-expected revenue and profits, prompting a surge of optimism from investors and analysts alike. By the next day (Nov 5), ZETA’s stock price had soared roughly 15% in heavy trading as the market digested the newsstockanalysis.com. This marked a sharp positive turnaround, especially considering that just a few months prior the stock was languishing near yearly lows. Financial media outlets dubbed Zeta’s Q3 a “beat-and-raise” performance

Stock Market Today

Meta stock faces an AI split: ad gains vs a $135 billion bill

Meta stock faces an AI split: ad gains vs a $135 billion bill

7 February 2026
Meta shares dropped 1.3% to $661.46 on Friday after the company projected 2026 capital spending of up to $135 billion, raising investor concerns over cash flow. Meta reported Q4 revenue of $59.89 billion, up 24% year-over-year, with ad impressions rising 18%. Analysts remain divided on whether AI-driven ad gains can offset the steep spending ramp.
IAG share price jumps toward a 52-week peak — what to watch before London reopens

IAG share price jumps toward a 52-week peak — what to watch before London reopens

7 February 2026
IAG shares rose 4.33% to 438.50 pence Friday, near their 52-week high, ahead of full-year results due later this month. The company reported 162,073,135 treasury shares and total voting rights of 4,565,128,012. Brent crude fell 2.2% Thursday to $67.93 a barrel. South Europe Ground Services logged 712,340 operations in 2025 and seeks approval to operate in Portugal.
Go toTop